Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Veracyte, Inc.
Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Allegro Diagnostics Corporation
- GenomeDx Inc.
- Decipher BioSciences Inc.
- HalioDx Inc.
- Inserm Transfert
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.